Floatz logo

Icotinib

MRD

Guangdong Association of Clinical TrialsSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the MRD cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
The First Affiliated Hospital of Soochow University
Phase 4BB
DARATUMUMAB
The First Affiliated Hospital of Soochow University
Phase 4BB
cc-5013
The First Affiliated Hospital of Soochow University
Phase 4BB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
Carfilzomib
The First Affiliated Hospital of Soochow University
Phase 4BB

View all 15 →

Same molecule, other indications

Icotinib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →